335 related articles for article (PubMed ID: 16208307)
1. The prevention of type 2 diabetes: what is the evidence?
Chiasson JL; Brindisi MC; Rabasa-Lhoret R
Minerva Endocrinol; 2005 Sep; 30(3):179-91. PubMed ID: 16208307
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and surgical intervention for the prevention of diabetes.
Chiasson JL
Nestle Nutr Workshop Ser Clin Perform Programme; 2006; 11():31-42. PubMed ID: 16820729
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
4. Preventing type II diabetes mellitus.
Prisant LM
J Clin Pharmacol; 2004 Apr; 44(4):406-13. PubMed ID: 15051749
[TBL] [Abstract][Full Text] [Related]
5. Diabetes prevention: is there more to it than lifestyle changes?
Gruber A; Nasser K; Smith R; Sharma JC; Thomson GA
Int J Clin Pract; 2006 May; 60(5):590-4. PubMed ID: 16700860
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic prevention or delay of type 2 diabetes mellitus.
Anderson DC
Ann Pharmacother; 2005 Jan; 39(1):102-9. PubMed ID: 15562143
[TBL] [Abstract][Full Text] [Related]
7. Reflecting on type 2 diabetes prevention: more questions than answers!
Rosenstock J
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
[TBL] [Abstract][Full Text] [Related]
8. Prevention of type 2 diabetes.
Lai LC
Malays J Pathol; 2002 Dec; 24(2):71-6. PubMed ID: 12887163
[TBL] [Abstract][Full Text] [Related]
9. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
[TBL] [Abstract][Full Text] [Related]
10. Can type 2 diabetes mellitus be considered preventable?
Jermendy G
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S73-81. PubMed ID: 15955380
[TBL] [Abstract][Full Text] [Related]
11. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
12. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
Scheen AJ
Diabetes Metab; 2007 Feb; 33(1):3-12. PubMed ID: 17258489
[TBL] [Abstract][Full Text] [Related]
13. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.
Haffner SM
Am J Med; 2006 May; 119(5 Suppl 1):S3-9. PubMed ID: 16563945
[TBL] [Abstract][Full Text] [Related]
14. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
Delorme S; Chiasson JL
Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
16. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Type 2 diabetes: fact or fiction?
Chiasson JL
Expert Opin Pharmacother; 2007 Dec; 8(18):3147-58. PubMed ID: 18035959
[TBL] [Abstract][Full Text] [Related]
18. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
19. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
[TBL] [Abstract][Full Text] [Related]
20. Prevention of type 2 diabetes--lessons we have learnt for implementation.
Schwarz PE; Peltonen M
Horm Metab Res; 2007 Sep; 39(9):636-41. PubMed ID: 17846970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
